Join the club for FREE to access the whole archive and other member benefits.


Company focused on medical research and development for tissue-level regeneration

Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.

Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.

Visit website:




Details last updated 13-Dec-2019

People at Biosplice

Darrin Beaupre

Chief Medical Officer, Oncology, at Biosplice Therapeutics

Biosplice News

Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021

Longevity Technology - 25-Feb-2022

Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.


Biosplice dosed first patient with cirtuvivint in phase 1 clinical trial

Global News - 17-Nov-2021

Evaluates the safety and anti-tumor efficacy of oral cirtuvivint in cancer patients


Developmental stages of anti-ageing treatments

Next Big Future - 09-Jun-2019

Two anti-ageing treatments in phase 3 clinical trials and four in phase 2 clinical trials

Topics mentioned on this page:
Regenerative Medicine, Medical Technology